Golden logoGolden logo
Advanced Search
PsiOxus Therapeutics

PsiOxus Therapeutics

PsiOxus Therapeutics is an oncolytic Vaccines founded in 2006 by Kerry Fisher.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

July 2012
PsiOxus Therapeutics raises a $22,000,000 series B round from Imperial Innovations, Invesco Perpetual and SR One.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Nick Paul
April 14, 2021
FierceBiotech
Bluebird bio has shown cancer gene therapy vectors boost the efficacy of its CAR-T therapy in mice. The study assessed the effect of giving bluebird's anti-EGFR CAR-T cells in combination with vectors in development at PsiOxus Therapeutics.
Amirah Al Idrus
April 7, 2021
FierceBiotech
Bristol Myers Squibb and PsiOxus are expanding their partnership--again. The duo first teamed up in June 2016 to study the latter's cancer-killing virus, inking a deal later that year to combine the virus with BMS' checkpoint inhibitor, Opdivo. Now, they're adding a second asset from PsiOxus to the mix.

References

Golden logo
By using this site, you agree to our Terms of Service.